Meeting
2022 ASCO Genitourinary Cancers Symposium
A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.
Authors
Hongsik Kim
Samsung Medical Center, Seoul, South Korea
Hongsik Kim , Ryul Kim , Joohyun Hong , Ghee Young Kwon , Chan Kyo Kim , Won Park , Wan Song , Hyun Hwan Sung , Byong Chang Jeong , Jung Yong Hong , Se Hoon Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
KCT0003804
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 494)
DOI
10.1200/JCO.2022.40.6_suppl.494
Abstract #
494
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
First Author: Xin-Gang Bi
Poster
2022 ASCO Annual Meeting
Interim results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy for patients with cT2-T4aN0M0 MIBC.
First Author: Tianxin Lin
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
First Author: Qiu-Yan Chen
Poster
2021 Genitourinary Cancers Symposium
Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.
First Author: Vadim S Koshkin